Lawson Kroeker Investment Management Inc. NE Grows Position in Elevance Health, Inc. (NYSE:ELV)

Lawson Kroeker Investment Management Inc. NE boosted its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 15.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 32,088 shares of the company’s stock after buying an additional 4,372 shares during the quarter. Elevance Health accounts for about 2.2% of Lawson Kroeker Investment Management Inc. NE’s holdings, making the stock its 12th largest position. Lawson Kroeker Investment Management Inc. NE’s holdings in Elevance Health were worth $11,837,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Mutual Advisors LLC lifted its position in shares of Elevance Health by 2.5% in the fourth quarter. Mutual Advisors LLC now owns 2,163 shares of the company’s stock valued at $833,000 after acquiring an additional 52 shares in the last quarter. Czech National Bank lifted its position in shares of Elevance Health by 6.5% in the fourth quarter. Czech National Bank now owns 50,286 shares of the company’s stock valued at $18,551,000 after acquiring an additional 3,049 shares in the last quarter. Iridian Asset Management LLC CT lifted its position in shares of Elevance Health by 10.7% in the third quarter. Iridian Asset Management LLC CT now owns 39,154 shares of the company’s stock valued at $20,360,000 after acquiring an additional 3,786 shares in the last quarter. International Assets Investment Management LLC lifted its position in shares of Elevance Health by 85,533.1% in the third quarter. International Assets Investment Management LLC now owns 532,638 shares of the company’s stock valued at $276,972,000 after acquiring an additional 532,016 shares in the last quarter. Finally, Benjamin Edwards Inc. lifted its position in shares of Elevance Health by 1,711.9% in the third quarter. Benjamin Edwards Inc. now owns 53,559 shares of the company’s stock valued at $27,858,000 after acquiring an additional 50,603 shares in the last quarter. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Elevance Health Stock Down 1.2 %

Shares of NYSE:ELV opened at $400.62 on Thursday. Elevance Health, Inc. has a 1 year low of $362.21 and a 1 year high of $567.26. The business has a 50 day simple moving average of $386.65 and a two-hundred day simple moving average of $459.57. The firm has a market capitalization of $92.91 billion, a PE ratio of 14.61, a price-to-earnings-growth ratio of 1.11 and a beta of 0.84. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.50 and a quick ratio of 1.50.

Elevance Health (NYSE:ELV) last announced its earnings results on Thursday, January 23rd. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.80 by $0.04. Elevance Health had a return on equity of 19.56% and a net margin of 3.68%. On average, equities analysts predict that Elevance Health, Inc. will post 32.95 EPS for the current year.

Elevance Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 25th. Investors of record on Monday, March 10th will be issued a $1.71 dividend. This is a positive change from Elevance Health’s previous quarterly dividend of $1.63. The ex-dividend date of this dividend is Monday, March 10th. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.71%. Elevance Health’s payout ratio is presently 26.71%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on ELV shares. StockNews.com cut Elevance Health from a “buy” rating to a “hold” rating in a report on Monday. UBS Group reduced their target price on Elevance Health from $605.00 to $555.00 and set a “buy” rating on the stock in a report on Friday, October 18th. Truist Financial reduced their target price on Elevance Health from $520.00 to $480.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Royal Bank of Canada reduced their target price on Elevance Health from $585.00 to $478.00 and set an “outperform” rating on the stock in a report on Friday, October 18th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $485.00 target price on shares of Elevance Health in a report on Friday, January 24th. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Elevance Health has a consensus rating of “Moderate Buy” and a consensus target price of $517.03.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.